



Buprenorphine is a Schedule III controlled substance commonly prescribed for opioid use disorder (OUD) treatment. In 2025, new federal rules have significantly expanded access to buprenorphine via telemedicine, allowing practitioners to prescribe up to a six-month initial supply through audio-only or audio-video consultations without requiring an in-person evaluation.

Before prescribing, practitioners must review the patient's prescription drug monitoring program (PDMP) history and document this review. If PDMP data is unavailable, only a limited seven-day supply may be prescribed, with further prescriptions contingent on subsequent PDMP checks. After the initial six-month supply, additional buprenorphine prescriptions generally require different telemedicine modalities or an in-person visit.

Pharmacists must verify patient identity with government-issued ID when dispensing. The DEA is also proposing special registrations to allow qualified practitioners and telemedicine platforms to prescribe Schedule II-V substances under specific conditions.

In summary, buying buprenorphine online with immediate dispatch in 2025 is possible with a valid prescription from a licensed DEA-registered practitioner, following expanded telemedicine rules that facilitate remote access for OUD treatment. Dispensing is through authorized pharmacies that comply with identity verification and regulatory safeguards.